Morgan Stanley Roivant Sciences Ltd. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Morgan Stanley holds 44,693,966 shares of ROIV stock, worth $875 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

44,693,966

Previous 35,926,759 24.4%

Holding current value

$875 Million

Previous $363 Million 38.95%

% of portfolio

0.03%

Previous 0.03%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$9.08 - $11.62 $79.6 Million - $102 Million	8,767,207 Added 24.4%	44,693,966 $504 Million
Q1 2025 May 15, 2025	BUY	$10.09 - $12.08 $13.2 Million - $15.8 Million	1,311,686 Added 3.79%	35,926,759 $363 Million
Q4 2024 Feb 14, 2025	BUY	$11.16 - $12.71 $55.1 Million - $62.8 Million	4,941,069 Added 16.65%	34,615,073 $409 Million
Q3 2024 May 14, 2025	BUY	$10.17 - $12.5 $3.5 Million - $4.3 Million	343,865 Added 1.17%	29,674,004 $342 Million
Q3 2024 Nov 14, 2024	BUY	$10.17 - $12.5 $3.5 Million - $4.3 Million	343,865 Added 1.17%	29,674,004 $342 Million
Q2 2024 May 14, 2025	SELL	$10.36 - $11.74 $54.8 Million - $62 Million	-5,284,934 Reduced 15.27%	29,330,139 $310 Million
Q2 2024 Oct 17, 2024	SELL	$10.36 - $11.74 $65.3 Million - $74 Million	-6,305,362 Reduced 17.69%	29,330,139 $310 Million
Q2 2024 Aug 14, 2024	SELL	$10.36 - $11.74 $65.3 Million - $74 Million	-6,305,362 Reduced 17.69%	29,330,139 $310 Million
Q1 2024 Oct 17, 2024	BUY	$9.87 - $11.8 $62.2 Million - $74.4 Million	6,305,362 Added 21.5%	35,635,501 $376 Million
Q1 2024 Aug 16, 2024	BUY	$9.87 - $11.8 $135 Million - $162 Million	13,708,457 Added 62.52%	35,635,501 $376 Million
Q1 2024 May 15, 2024	BUY	$9.87 - $11.8 $135 Million - $162 Million	13,708,457 Added 62.52%	35,635,501 $376 Million
Q4 2023 Aug 16, 2024	SELL	$8.38 - $11.58 $62 Million - $85.7 Million	-7,403,095 Reduced 25.24%	21,927,044 $246 Million
Q4 2023 Feb 13, 2024	BUY	$8.38 - $11.58 $21.9 Million - $30.3 Million	2,615,413 Added 13.54%	21,927,044 $246 Million
Q3 2023 Nov 15, 2023	BUY	$9.76 - $13.19 $61.7 Million - $83.4 Million	6,324,915 Added 48.7%	19,311,631 $226 Million
Q2 2023 Aug 14, 2023	BUY	$7.09 - $10.08 $69.6 Million - $98.9 Million	9,810,452 Added 308.87%	12,986,716 $131 Million
Q1 2023 May 15, 2023	BUY	$6.92 - $9.98 $19.6 Million - $28.3 Million	2,831,760 Added 821.98%	3,176,264 $23.4 Million
Q4 2022 Feb 14, 2023	BUY	$3.36 - $7.99 $1.02 Million - $2.42 Million	303,340 Added 736.91%	344,504 $2.75 Million
Q3 2022 Nov 14, 2022	BUY	$0.51 - $4.84 $7,640 - $72,512	14,982 Added 57.22%	41,164 $132,000
Q2 2022 Oct 27, 2022	BUY	$2.81 - $4.84 $72,691 - $125,205	25,869 Added 8264.86%	26,182 $106,000
Q2 2022 Aug 15, 2022	BUY	$2.81 - $4.84 $72,691 - $125,205	25,869 Added 8264.86%	26,182 $106,000
Q1 2022 Oct 27, 2022	SELL	$4.74 - $9.91 $122,619 - $256,361	-25,869 Reduced 98.8%	313 $2,000
Q1 2022 May 13, 2022	SELL	$4.74 - $9.91 $2,023 - $4,231	-427 Reduced 57.7%	313 $2,000
Q4 2021 Feb 14, 2022	BUY	$5.86 - $13.52 $4,336 - $10,004	740 New	740 $7,000

Others Institutions Holding ROIV

# of Institutions

364

Shares Held

455M

Call Options Held

8.36M

Put Options Held

760K

View Full List

About Roivant Sciences Ltd.

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $13.8B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

More about ROIV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account